Comment on the Q3 Report and EU approval for third line treatment

CEO Sofia Heigis and CFO Henrik Bergentoft comment on the Q3 report – sales up 41 percent to SEK 28.5 million and, for the first time, more than SEK 100 million in rolling twelve-month sales – and on the EU approval for the third line of treatment, which doubles the addressable patient population, how the launch looks in Germany, Italy and Spain, and why the German price negotiation affects the rest of Europe.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com